Trial Profile

A Phase 2, Two-Arm, Double-Blind, Multi-Center, Randomized Study of the Combination of Oral WX-671 [Wilex] Plus Capecitabine [Xeloda; Hoffman La Roche AG] vs. Capecitabine Monotherapy in First-Line Her2-Negative Metastatic Breast Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
11 Apr 2013 Results will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO-2013) according to a WILEX media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com